Evidence map›Paper›PMID 27151405›Full record

ArticleBMC bioinformatics2016

DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.

Naiem T Issa, Jordan Kruger, Henri Wathieu, Rajarajan Raja, Stephen W Byers, Sivanesan Dakshanamurthy

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Naiem T IssaDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, 20057, USA.
Jordan KrugerDepartment of Biochemistry & Molecular Biology, Georgetown University, Washington DC, 20057, USA.
Henri WathieuGeorgetown University Medical Center, Washington DC, 20057, USA.
Rajarajan RajaGeorge Mason University, 4400 University Dr, Fairfax, VA, 22030, USA.
Stephen W ByersDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, 20057, USA.
Sivanesan DakshanamurthyDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, 20057, USA. sd233@georgetown.edu.
Georgetown University Medical Center · USGeorgetown University · USGeorge Mason University · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
Cadherin11 in cancer & rheumatoid arthritis: Common target, common therapies? (5)R01CA170653 · NCI · GEORGETOWN UNIVERSITY · PI BYERS, STEPHEN W · 2012 to 2015
$2.4M
NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA170653
6 · The paper itself

Abstract

backgroundThe targeting of disease-related proteins is important for drug discovery, and yet target-based discovery has not been fruitful. Contextualizing overall biological processes is critical to formulating successful drug-disease hypotheses. Network pharmacology helps to overcome target-based bottlenecks through systems biology analytics, such as protein-protein interaction (PPI) networks and pathway regulation.

resultsWe present a systems polypharmacology platform entitled DrugGenEx-Net (DGE-NET). DGE-NET predicts empirical drug-target (DT) interactions, integrates interaction pairs into a multi-tiered network analysis, and ultimately predicts disease-specific drug polypharmacology through systems-based gene expression analysis. Incorporation of established biological network annotations for protein target-disease, -signaling pathway, -molecular function, and protein-protein interactions enhances predicted DT effects on disease pathophysiology. Over 50 drug-disease and 100 drug-pathway predictions are validated. For example, the predicted systems pharmacology of the cholesterol-lowering agent ezetimibe corroborates its potential carcinogenicity. When disease-specific gene expression analysis is integrated, DGE-NET prioritizes known therapeutics/experimental drugs as well as their contra-indications. Proof-of-concept is established for immune-related rheumatoid arthritis and inflammatory bowel disease, as well as neuro-degenerative Alzheimer's and Parkinson's diseases.

conclusionsDGE-NET is a novel computational method that predicting drug therapeutic and counter-therapeutic indications by uniquely integrating systems pharmacology with gene expression analysis. DGE-NET correctly predicts various drug-disease indications by linking the biological activity of drugs and diseases at multiple tiers of biological action, and is therefore a useful approach to identifying drug candidates for re-purposing.

Indexed as

Drug InteractionsDrug RepositioningGene Expression RegulationSoftwareComputational BiologyDatabases as TopicDiseaseHumansProtein Interaction MapsProteinsReproducibility of ResultsSystems BiologyProteinsAlzheimer’s diseaseDrugGenEx-NETGene expression analysisInflammatory bowel diseaseParkinson’s diseasePolypharmacologyRheumatoid arthritisTMFS

Identifiers

PMID27151405
PMCPMC4857427
OpenAlexW2347089309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.